TriLink BioTechnologies Announces Worldwide License with QuantiBact A/S
News May 09, 2013
TINA molecules are intercalators placed at the 5' end of primers to stabilize duplex formation. Their unique properties improve the sensitivity and specificity of endpoint and real-time PCR. TINA may find applications wherever an enhanced Tm is required such as triplex formation or potentially even gene silencing.
"At QuantiBact we strive to make our technologies available throughout the research and diagnostic communities. We appreciate being able to work with dedicated companies that hold high recognition in the market place. The market position as well as in depth knowledge of nucleic acids embedded within TriLink will enable us to further reach our goal," says Palle Schelde, CEO, Managing Director, QuantiBact.
"At TriLink we pride ourselves on our quality and our ability to handle unique nucleic acid modifications. This makes us an ideal manufacturer of TINA oligos," stated Richard Hogrefe, Ph.D., President and CEO of TriLink. "We are excited to work with the great folks at Quantibact and see how this technology might advance molecular diagnostics."
First Multiplex Test for Tick-Borne DiseasesNews
A new blood test called the Tick-Borne Disease Serochip (TBD Serochip) promises to revolutionize the diagnosis of tick-borne disease by offering a single test to identify and distinguish between Borrelia burgdorferi, the pathogen responsible for Lyme disease, and seven other tick-borne pathogens.READ MORE
Duplicate Genes Offer a Explanation for Differences Between the SexesNews
A study in flies has identified the process by duplicating a gene can help resolve genetic sexual conflict.READ MORE
Inheritance and Cannibalism Shape the Termite Gut MicrobiomeNews
A huge new study has outlined what influences help create the incredibly diverse termite microbiome.READ MORE